Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • creative campaigns

    - PMLiVE

    NHS programme to give melanoma patients fast-track access to skin cancer vaccine

    The phase 2 study will evaluate Scancell's iSCIB1+ in patients with advanced unresectable melanoma

    - PMLiVE

    British Skin Foundation receives £10,000 donation from Circle Health Group

    The healthcare provider’s previous donation is supporting research into early melanoma detection

    - PMLiVE

    Merck shares positive ten-year results for Keytruda in advanced melanoma

    More than 100,640 cases of the skin cancer are expected to be diagnosed in the US this year

    - PMLiVE

    BioNTech shares promising results for mRNA immunotherapy candidate in advanced melanoma

    Melanoma is currently responsible for around 58,000 deaths globally every year

    - PMLiVE

    Moderna/Merck share positive three-year results for investigational skin cancer vaccine

    More than 100,000 new cases of melanoma are expected to be diagnosed in the US in 2024

    - PMLiVE

    FDA approves Iovance’s Amtagvi as first cellular therapy for advanced melanoma

    Amtagvi is now the first one-time, individualised T cell therapy to be approved in the US for a solid tumour cancer

    - PMLiVE

    Bristol Myers Squibb’s Opdualag approved by MHRA for advanced melanoma

    Approximately 17,000 cases of melanoma are diagnosed in the UK every year

    - PMLiVE

    Bristol Myers Squibb’s Opdivo approved by FDA for expanded melanoma use

    More than 97,000 cases of melanoma are expected to be diagnosed in the US in 2023

    - PMLiVE

    Bristol Myers Squibb to acquire Mirati Therapeutics for up to $5.8bn

    The transaction would mark a significant boost to the US drugmaker’s oncology portfolio

    - PMLiVE

    Bristol Myers Squibb’s Opdivo approved by EC for expanded melanoma use

    The global incidence of skin cancer has been rising steadily over the past few decades

    - PMLiVE

    Moderna and Merck’s skin cancer vaccine enters late-stage development

    More than 1,000 patients with resected high-risk melanoma will be enrolled in the trial

    - PMLiVE

    Bristol Myers Squibb’s Opdivo recommended by CHMP for expanded melanoma use

    The global incidence of skin cancer has been rising steadily over the past few decades

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links